Allspring Global Investments Holdings LLC Purchases 29,465 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Allspring Global Investments Holdings LLC grew its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 16.3% during the 3rd quarter, Holdings Channel reports. The firm owned 210,531 shares of the company’s stock after purchasing an additional 29,465 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Tarsus Pharmaceuticals were worth $6,924,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Jennison Associates LLC acquired a new position in Tarsus Pharmaceuticals in the first quarter valued at about $48,380,000. Assenagon Asset Management S.A. acquired a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at approximately $28,904,000. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Tarsus Pharmaceuticals by 1,113.5% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 898,000 shares of the company’s stock worth $32,642,000 after acquiring an additional 824,000 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Tarsus Pharmaceuticals during the first quarter valued at approximately $12,640,000. Finally, Millennium Management LLC increased its stake in Tarsus Pharmaceuticals by 1,259.3% in the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after purchasing an additional 322,942 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Up 1.3 %

Shares of NASDAQ:TARS opened at $39.41 on Monday. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -8.26 and a beta of 1.07. Tarsus Pharmaceuticals, Inc. has a 12 month low of $12.87 and a 12 month high of $42.50. The company’s fifty day simple moving average is $32.16 and its 200 day simple moving average is $31.21. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.10. The firm had revenue of $40.81 million for the quarter, compared to the consensus estimate of $31.30 million. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. During the same quarter last year, the business posted ($1.17) EPS. As a group, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Oppenheimer reissued an “outperform” rating and issued a $63.00 target price (up from $61.00) on shares of Tarsus Pharmaceuticals in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $51.60.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.